Drug Trial Radar · NCT00998088
Blood Management in Orthopedic Surgery
Last checked: Nov 20, 2026Latest source record: Oct 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,598
Actual
Start
May 2004
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Sanquin Research & Blood Bank DivisionsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development; Roche BV Netherlands; Haemonetics Corporation
- First posted
- Oct 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Aim: to investigate whether the use of several transfusion alternatives (erythropoietin, the cell-saver or postoperative drainage and reinfusion systems) in patients undergoing elective total knee or hip replacement surgery can lead to allogeneic red blood cell (RBC) saving if a restrictive transfusion policy is used. Study design: a prospective, double randomized, open, multicenter study in which patients are stratified according to their preoperative hemoglobin(Hb) level: stratum I= Hb between 6,1 and 8,2 mmol/l. These patients are first randomized for Erythropoetin (Epo) or no Epo. Stratum II= Hb of 6,1 and lower or 8,2 mmol/l and higher, are not eligible for Epo and thus not randomized. Patients in both strata will be randomized for three modalities: a cell saver (CS)(to wash, filter and reinfuse autologous shed blood) which is used intra- and postoperatively or a postoperative autologous reinfusion drainage system (D) only (to filter and reinfuse autologous shed blood) or a restrictive transfusion trigger only (controls). Inclusion criteria: All orthopedic patients of 18 years and older being considered for a primary or revision total knee- (TKR) or total hip replacement (THR). Outcome measures: Primary outcome: number of allogeneic red blood cell (RBC) transfusions. Secondary outcome: transfusion reactions, rehabilitation time, length of hospital stay (days), peri- and post-operative complications during hospitalization, quality of life, cost analysis
Conditions
- Osteoarthritis
Interventions
erythropoietin and cell saverOther
weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
erythropoietinDrug
weekly 40.000 IU s.c. for 4 weeks pre-operatively
OrthoPATDevice
for intra- and post-operative re-infusion of autologous wound blood
Post-operative drain deviceDevice
For post-operative re-infusion of unwashed wound blood
Erythropoietin and OrthoPATOther
weekly 40.000 IU s.c. for 4 weeks pre-operatively
Erythropoietin and drain deviceOther
weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
OrthoPATDevice
For intra- and post-operative reinfusion of autologous blood
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of allogeneic red blood cell (RBC) transfusions.Time frame: up to 3 months after surgery
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Slotervaart Hospital
Amsterdam, North Holland, Netherlands
Albert Schweitzer Hospital
Dordrecht, South Holland, Netherlands
Groene Hart Hospital
Gouda, South Holland, Netherlands
LUMC
Leiden, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.